drugset / Trial / NCT07114107

Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion

NCT07114107

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective study. It enrolls subjects with allergic rhinitis, with or without asthma, who have nasal congestion as the main symptom and meet the inclusion criteria, aiming to evaluate the efficacy and safety of acoustic vibration combined with an oscillating positive expiratory pressure device in the treatment of patients with nasal congestion. On the premise that subjects agree to use basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA), they are instructed to use the acoustic vibration therapy device and the oscillating positive expiratory pressure therapy device respectively, 3 times a day for 3 minutes each time. Indicators related to nasal congestion will be measured immediately after a single use, as well as at 2 weeks, 4 weeks, and 8 weeks of use, so as to monitor the improvement of nasal ventilation and accompanying symptoms in the subjects.

Timeline

Start
2025-08
Primary completion
2026-03
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Background Ebastine Small molecule 10 mg
Background Mometasone furoate Other / unclassified 100 ug Intranasal
Background budesonide/formoterol Unknown 160 ug Inhaled
Background budesonide/formoterol Unknown 320 ug Inhaled
Background salmeterol/fluticasone propionate Unknown 100 ug Inhaled
Background salmeterol/fluticasone propionate Unknown 250 ug Inhaled
Background salmeterol/fluticasone propionate Unknown 500 ug Inhaled